Thirdly, looking at the figures provided in the literature referred to in point 107 of this Opinion, which show that the market share of the parallel importers increased from 1.8% to 6.8% between 1998 and 2003, 67one has the impression that the real battle is about winning back these profit margins which the rivals of the big pharmaceutical companies have appropriated.
Kolmandaks, võrreldes käesoleva ettepaneku punktis 107 mainitud õiguskirjanduses esitatud andmeid, mille kohaselt paralleelimportijate turuosa suurenes 1998. ja 2003. aasta vahel 1,8%-lt 6,8%-le, 67siis jääb mulje, et tõeline lahing käib kasumimarginaalide pärast, mille said suurte ravimitootjate rivaalid.